363 related articles for article (PubMed ID: 26613690)
21. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
22. Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013.
Raesima MM; Forhan SE; Voetsch AC; Hewitt S; Hariri S; Wang SA; Pelletier AR; Letebele M; Pheto T; Ramogola-Masire D; El-Halabi S
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(40):1147-9. PubMed ID: 26468997
[TBL] [Abstract][Full Text] [Related]
23. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
[TBL] [Abstract][Full Text] [Related]
24. Bug breakfast in the bulletin: the early impact of the national HPV vaccination program.
Quinn E; Donovan B; Sheppeard VK
N S W Public Health Bull; 2012 Dec; 23(9-10):208. PubMed ID: 23442998
[No Abstract] [Full Text] [Related]
25. Human papillomavirus vaccine disease impact beyond expectations.
de Sanjose S; Brotons M; LaMontagne DS; Bruni L
Curr Opin Virol; 2019 Dec; 39():16-22. PubMed ID: 31382121
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
27. An overview on the implementation of HPV vaccination in Europe.
Bonanni P; Levi M; Latham NB; Bechini A; Tiscione E; Lai P; Panatto D; Gasparini R; Boccalini S
Hum Vaccin; 2011; 7 Suppl():128-35. PubMed ID: 21245659
[TBL] [Abstract][Full Text] [Related]
28. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
30. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010.
Laugesen MJ; Mistry R; Carameli KA; Ribisl KM; Needleman J; Bastani R
J Adolesc Health; 2014 Nov; 55(5):659-64. PubMed ID: 24928803
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
32. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
33. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam.
Poulos C; Yang JC; Levin C; Van Minh H; Giang KB; Nguyen D
Soc Sci Med; 2011 Jul; 73(2):226-34. PubMed ID: 21733609
[TBL] [Abstract][Full Text] [Related]
34. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates.
Jeudin P; Liveright E; Del Carmen MG; Perkins RB
Clin Ther; 2014 Jan; 36(1):24-37. PubMed ID: 24417783
[TBL] [Abstract][Full Text] [Related]
35. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
36. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
37. HPV vaccines: state of the art.
D'Andrilli G; Bovicelli A; Giordano A
J Cell Physiol; 2010 Sep; 224(3):601-4. PubMed ID: 20432468
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?
Osazuwa-Peters N
Vaccine; 2013 Nov; 31(47):5500-5. PubMed ID: 24095883
[TBL] [Abstract][Full Text] [Related]
39. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
